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Introduction: In women with breast cancer who smoke, it is unclear whether smoking could impair their survival
from the disease.
Methods: We examined the relation of smoking at diagnosis to breast cancer-specific and overall survival among
5,892 women with invasive breast cancer treated in one Canadian center (1987 to 2008). Women were classified as
never, former or current smokers. Current smokers were further classified according to total, intensity and duration
of smoking. Deaths were identified through linkage to population mortality data. Cox proportional-hazards multivariate
models were used. A systematic review with meta-analysis combines new findings with published results.
Results: Compared with never smokers, current smokers at diagnosis had a slightly, but not statistically significant,
higher breast cancer-specific mortality (hazard ratio = 1.15, 95% confidence interval (CI): 0.97 to 1.37). Among current
smokers, breast cancer-specific mortality increased with total exposure to, intensity and duration of smoking (all
Ptrend <0.05). Compared to never smokers, breast cancer-specific mortality was 32 to 56% higher among heavy
smokers (more than 30 pack years of smoking, more than 20 cigarettes per day or more than 30 years of smoking).
Smoking at diagnosis was associated with an increased all-cause mortality rate. A meta-analysis of all studies showed a
statistically significant, 33% increased mortality from breast cancer in women with breast cancer who are smokers at
diagnosis compared to never smokers (hazard ratio = 1.33, 95% CI: 1.12 to 1.58).
Conclusions: Available evidence to date indicates that smoking at diagnosis is associated with a reduction of
both overall and breast cancer-specific survival. Studies of the effect of smoking cessation after diagnosis on
breast cancer-specific outcomes are needed.Introduction
Women with breast cancer are eager to do what they
can to improve their prognosis [1]. However, apart from
weight control and regular physical activity [2,3], there
are few lifestyle changes that are known to improve the
prognosis of the disease.
Smoking cessation is perhaps a lifestyle choice that
women with breast cancer could make to improve their
prognosis. Numerous studies show that smoking is associ-
ated with a reduction of overall survival among smokers* Correspondence: jacques.brisson@uresp.ulaval.ca
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reproduction in any medium, provided the orwho are diagnosed with breast cancer [4-14]. This de-
creased survival is attributable, at least in part, to in-
creased mortality from causes other than breast cancer
that are associated with smoking.
Some studies have suggested that smoking at diagnosis
may also be associated with increased mortality from
breast cancer itself. However, while some studies observed
such an increase in post-diagnosis breast cancer-specific
mortality in smokers [4,5,8,11,12,15], this increase was sta-
tistically significant in five studies [4,5,8,12,15] but some
studies showed little or no association between smoking
and breast cancer survival [6,9,16].
Clarification of whether smoking could affect breast
cancer-specific mortality is important as it would shape
survivorship health messages to the large population of
smokers who are diagnosed with the disease. This studyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cer diagnosis to long-term breast cancer-specific survival
and overall survival, in a large cohort of women diag-
nosed with and treated for invasive breast cancer be-
tween 1987 and 2008 at one Breast Center in Quebec
City, Canada. In addition, a systematic review with meta-
analysis is also reported combining the present findings
with all available published results on smoking and breast
cancer-specific survival.
Methods
Smoking at diagnosis and survival: new findings
Study population
From January 1987 through May 2008, 6,377 women
were diagnosed with primary invasive breast carcinoma
and received their initial treatments at the ‘Centre des
maladies du sein Deschênes-Fabia - CMSDF.’ This ana-
lysis is based on the 5,892 (92.4%) cases with known
smoking status at diagnosis; most cases are whites of
European descent. Since data were collected from pa-
tient’s charts without contact with participants, access to
charts was authorized by the Director of professional
services and the study was approved by the Research
Ethics Review Board of our center (Centre hospitalier
affilié universitaire de Québec, Quebec, Quebec, Canada)
without the need for individual patient’s consent.
Data collection
Information on smoking at diagnosis and several charac-
teristics of women was extracted from a registry held by
the CMSDF.
At diagnosis, women were asked whether they had
ever smoked cigarettes and, if so, the usual number of
cigarettes smoked daily, for how many years they had
smoked and whether they were still smoking. Other
characteristics collected include year of diagnosis, age,
height and weight, obstetrical and gynecological history,
first degree family history of breast cancer and alcohol
consumption. The presence of comorbid conditions
[17,18] in the six-month period preceding the diagno-
sis of breast cancer, including diabetes and its chronic com-
plications, was assessed by record linkage with MED-ECHO
files, a comprehensive population-based hospitalization
and day-surgery data base. This database includes one
principal diagnosis and up to 15 secondary diagnoses
at the time of any hospitalization or day-surgery.
Characteristics of the disease including estrogen and
progesterone receptor status, histological grade [19],
tumor size, and regional or distant involvement were
also recorded in the Breast Center registry as well as
treatments including initial surgical treatments, neoadju-
vant and adjuvant therapy (endocrine therapy, chemo-
therapy and, more recently, the monoclonal antibody
Herceptin®).Information on women’s vital status was determined
up to 31 October 2008 (the termination date for the
present analysis), by linking personal identifying infor-
mation to the database of beneficiaries of the Quebec
universal health insurance system, and to the Quebec
mortality database held by the ‘Institut de la statistique
du Québec, ISQ.’ Causes of death, which were extracted
from the ISQ database, were coded based on the Inter-
national Classification of Diseases; breast cancer deaths
were those coded 174.9 (Ninth revision until 1999) and
C50.9 (Tenth revision thereafter).
Statistical analysis
The date of diagnosis was defined, in order of priority,
as the date of: 1) the first histopathological confirmation
of the malignancy (available in 98.4% of cases), 2) the
first positive cytology, or 3) the first clinical investigation
(mainly mammography) showing malignancy. For most
women (n = 5,868), person-years of follow-up were cal-
culated from the date of diagnosis of breast cancer until
the earliest of date of death or 31 October 2008. Women
who did not match with administrative databases (n = 13)
and those identified as being no longer covered by the
Quebec health insurance (n = 11) were censored at the
date of their last visit at the Breast Center or at the date of
interruption of the insurance coverage, respectively.
For descriptive purposes, breast cancer-specific and
overall survival rates following the diagnosis were cal-
culated by the actuarial method with one-year time in-
tervals using death from breast cancer or of any cause,
respectively, as endpoint. Deaths of unknown cause
(14 cases, representing 1% of all deaths) were consid-
ered to be due to causes other than breast cancer.
Baseline characteristics were presented according to
smoking status.
Cox proportional hazards models were used to calcu-
late hazard ratios (HR) and 95% confidence intervals
(CI) of death from breast cancer (breast cancer-specific
mortality HRs) and death from any cause (overall mortal-
ity HRs). HRs (and 95% CIs) were calculated for smoking
categories (never, former, current) with never smokers as
the reference group. Current smokers were further classi-
fied according to categories of total exposure to smoking,
computed as the product of duration of smoking and
mean number of packs (20 cigarettes) smoked per day
(≤15, >15 to 30, >30 pack years), categories of intensity of
smoking (≤10, 10 to 20, >20 cigarettes/day) and categories
of duration of smoking (≤20, 21 to 30, >30 years). In these
same Cox models, P values for trend in HRs according to
total, intensity and duration of smoking are based on
the Wald test of the linear contrast between the four
categories compared (never smokers and the three cat-
egories of current smokers) [20]. Former smokers were
excluded from this contrast. Finally, there was no
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was violated whether based on the inspection of plots
of log(−log(survival)) versus log of survival time curves
or on statistical tests [21].
In all multivariate Cox models, adjustments were
made for a large set of factors known or suspected to
confound the relation of smoking to breast cancer risk
[22-25] or to prognosis of breast cancer [2,25-28]: year
of diagnosis, age at diagnosis, age at menarche, parity,
menopausal status, current hormone replacement ther-
apy use, first degree family history of breast cancer, es-
trogen and progesterone receptor positivity, histological
grade, size of the tumor, regional or distant involvement,
locoregional treatment, neoadjuvant therapy, adjuvant
endocrine therapy and adjuvant chemotherapy. Adjuvant
treatment with Herceptin (trastuzumab) was not consid-
ered in the present analysis: it has been available only
since 2005 in our center, and was used by less than 150
cases participating in the present analysis. However, tras-
tuzumab has been found to offer similar benefits to
smokers and non-smokers [29]. Multiple imputation tech-
niques [30,31] were used to handle missing data on poten-
tial confounders. For each of the two outcomes (breast
cancer-specific mortality and overall mortality), 50 im-
puted datasets were generated and results were combined
using the PROC MI and PROC MIANALYZE commands
in SAS (version 9.3) with appropriate correction for vari-
ance. The data imputation models included the outcome
variables (survival time, vital status and cause of death,
and an interaction term between survival time and out-
come), smoking status and smoking exposure variables
among smokers (total, intensity and duration), all poten-
tial confounders above, alcohol use, and a few additional
variables (weight and height, clinical tumor size). Sensitiv-
ity analyses were performed. First, results obtained in the
entire cohort of 5,892 women with multiple imputation
were compared to those obtained with the subset of 4,334
subjects for whom all data (except alcohol use) were avail-
able (complete case analysis [32]). Second, analyses were
performed on the entire cohort of 5,892 women using in-
dicator variables for missing data on confounders. Third,
since alcohol use was not collected among women diag-
nosed in 1999 to 2003, and was thus missing on nearly
half the cases, confounding by alcohol use (yes, no) was
assessed in the entire cohort (n = 5,892) with multiple im-
putation, and also in the subset of cases (n = 2,315) with
complete data including alcohol use and in the analysis
using missing indicator variables to handle missing data
on the other confounders (n = 3099). Fourth, an analysis
was done to assess the effect of adjustment for different
covariates. Models additionally adjusted for body mass
index and diabetes were computed. Also, smoking has
been hypothesized to increase breast cancer-specific mor-
tality by promoting more aggressive tumors [8,9,11,16] orbecause smokers experience delay in diagnosis and
treatment of their disease [9,11]. Thus, such character-
istics could be viewed as intermediate factors in the
pathway relating smoking to breast cancer-specific mortal-
ity. The effect of adjustment for individual co-variable or
groups of co-variables was investigated by comparing
the smoking HR obtained from a fully-adjusted model
to the smoking HR obtained from a model that ex-
cluded one co-variable or a group of co-variables (for
instance exclusion from a model of grade, hormonal
receptor status, tumor size or stage at diagnosis indi-
vidually or exclusion of grade and hormonal receptor
status (representing the biology of the tumor), or ex-
clusion of tumor size and stage at diagnosis (represent-
ing the extent of disease at diagnosis) or exclusion of
all these tumor related co-variables (representing tumor
characteristics). Finally, interactions of smoking status
with age at diagnosis, menopausal status, body mass
index, ER/PR status, regional or distal involvement and
treatments were assessed.
Statistical significance was based on two-sided P values.
All statistical analyses were carried out by using the
Statistical Analysis System (SAS Institute, Cary, NC,
USA version 9.3).
Systematic review and meta-analysis of published
findings
Published cohort studies on the relation of smoking to
breast cancer-specific survival were identified from PubMed
(up to 4 July 2013) using the medical subject headings
(MeSH) terms ("Breast Neoplasms"[Majr:NoExp]) AND
((((("Survival"[Mesh]) OR "Mortality"[Mesh]) OR "Survival
Rate"[Mesh]) OR "Disease-Free Survival"[Mesh]) OR "Sur-
vival Analysis"[Mesh] OR Mortality OR Survival) AND
("Habits"[Mesh]). Only English and French language pa-
pers were eligible for inclusion. Bibliographies of retrieved
papers were also searched. The relevance of each of the
papers identified was judged independently by two of us
(SB and JB) based on the title or abstract and then the re-
trieved paper. For all retained papers, detailed data were
extracted including HR (95% CI) for current smoking as
compared to never smokers, adjustment variables and var-
iables used for stratified analyses. The quality of studies
was assessed using the Newcastle-Ottawa Scale, a stan-
dardized tool [33].
The meta-analysis was performed using REVMAN stat-
istical software (version 5.1) [34]. Summary HRs and 95%
CIs were estimated using the random-effects model. Het-
erogeneity between studies was assessed using the I2 stat-
istic and the Cochran Q test.
Sensitivity analysis was performed to examine the ef-
fect on both the summary HRs and the heterogeneity as-
sessment of excluding studies most likely responsible for
heterogeneity between studies.
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Smoking and survival in the cohort
The 5,892 women with invasive breast cancer included in
the analyses accumulated 41,255 person-years of follow-up;
53.9% of breast cancer cases were followed for at least
5 years, 25.7% at least 10 years, and 11.4% at least 15 years
(maximum: 22 years). During the follow-up period, 1,408
deaths were documented, of which 953 (67.7%) were from
breast cancer, 441 (31.3%) from other causes and 14 (1.0%)
from unknown causes. The five-year and ten-year breast
cancer-specific survival estimates were 87% and 79%, re-
spectively, and five-year and ten-year overall survival esti-
mates were 83% and 71%, respectively.
At diagnosis, 60% of women reported having never
smoked, 22% were former smokers and 18% were
current smokers (Table 1). Current smokers appeared
to be younger, leaner and more likely to be alcohol
drinkers compared with never smokers. Characteristics ofTable 1 Characteristics of women with invasive breast cancer
Current (n = 1,079)
Characteristics of women
Age (years), mean (SD) 52.8 (11.5)
Body mass indexb (kg/m2), mean (SD) 24.0 (4.6)
Age (years) at menarcheb, mean (SD) 12.8 (1.8)
Parityb, mean (SD) 1.9 (1.8)
Postmenopausal womenb (%) 60.5
Age (years) at menopauseb, mean (SD) 45.4 (6.9)
Hormone replacement therapy current useb (%) 17.1
Family history of breast cancera, b (%) 23.2
Diabetesb (%) 1.9
Current alcohol intakeb (%) 39.5
Characteristics of the disease and treatment
Tumor size (mm)b, mean (SD) 22.9 (17.7)
Number of axillary nodes examinedb, c, mean (SD) 12.4 (7.8)
Positive estrogen receptors (%) 73.3
Positive progesterone receptors (%) 56.1
Well differentiated histological gradeb (%) 24.5
Regional involvement (%) 39.4
Distant metastasis at diagnosis (%) 3.2
Breast-conserving surgeryd (%) 68.3
Axillary surgeryd (%) 89.4
Neoadjuvant therapyd (%) 5.4
Adjuvant radiotherapyb, d (%) 75.9
Adjuvant chemotherapyb, d (%) 49.0
Adjuvant endocrine therapyb, d (%) 60.8
aMother, sister and daughter. bMissing information in less than 5% of women, exce
use (47.4%). cIn 5,132 women who had an axillary surgery or a sentinel node biothe disease and treatment differed little according to
smoking status.
Based on unadjusted models, there was no statistically
significant association between smoking at diagnosis
(status, total exposure, intensity or duration) and breast
cancer-specific mortality (Table 2). The effects of total
smoking exposure, intensity and duration of smoking
became more apparent after taking age at diagnosis into
account. Based on multivariate adjusted models, breast
cancer-specific mortality was 4% (HR = 1.04, 95% CI:
0.88 to 1.24) and 15% (HR = 1.15, 95% CI: 0.97 to 1.37)
higher in former and current smokers at diagnosis, re-
spectively, compared to never smokers at diagnosis,
but this association was not statistically significant
(Passociation = 0.30). However, there was a trend for in-
creased HRs with increasing pack years of smoking at
diagnosis (Ptrend = 0.002), with increasing number of
cigarettes smoked daily (Ptrend = 0.03) and with increasingaccording to smoking status at diagnosis (1987 to 2008)
Smoking status at time of diagnosis
Former (n = 1,303) Never (n = 3,510) Total (n = 5,892)
56.1 (11.3) 59.3 (13.1) 57.4 (12.7)
25.5 (5.0) 25.1 (4.7) 25.0 (4.8)
12.8 (1.7) 12.9 (1.6) 12.9 (1.7)
1.9 (1.8) 2.3 (2.2) 2.1 (2.1)
67.6 73.6 69.8





22.7 (17.5) 23.3 (18.3) 23.1 (18.0)












pt for histological grade (14%), pathological tumor size (6.1%), and alcohol
psy. dIn 5,713 women with nonmetastatic breast cancer.
Table 2 Breast cancer-specific mortality according to smoking exposure at time of diagnosis among 5,892 women with
invasive breast cancer (1987 to 2008)
Smoking status Breast cancer-specific mortality
Number of Crude HR (95% CI) Agea-adjusted HR (95% CI) Adjustedb HR (95% CI)
Women Deaths
Neverc 3,510 583 1.00 1.00 1.00
Former 1,303 185 0.94 (0.79 to 1.11) 0.99 (0.84 to 1.17) 1.04 (0.88 to 1.24)
Currentd 1,079 185 0.99 (0.84 to 1.16) 0.99 (0.83 to 1.17) 1.15 (0.97 to 1.37)
≤15 pack years 232 40 0.82 (0.60 to 1.13) 0.73 (0.53 to 1.01) 0.92 (0.66 to 1.28)
>15 to ≤30 pack years 278 54 1.06 (0.80 to 1.40) 1.05 (0.79 to 1.39) 1.23 (0.92 to 1.64)
>30 pack years 273 58 1.20 (0.91 to 1.57) 1.35 (1.03 to 1.78) 1.52 (1.15 to 2.00)
P-value, test for trende 0.08 0.004 0.002
≤10 cigarettes/day 287 36 0.75 (0.54 to 1.05) 0.73 (0.52 to 1.02) 0.97 (0.69 to 1.37)
>10 to ≤20 cigarettes/day 395 75 1.05 (0.83 to 1.34) 1.06 (0.83 to 1.35) 1.13 (0.88 to 1.45)
>20 cigarettes/day 337 70 1.17 (0.91 to 1.50) 1.19 (0.92 to 1.53) 1.32 (1.02 to 1.70)
P-value, test for trende 0.06 0.04 0.03
≤20 years 191 44 1.06 (0.78 to 1.44) 0.87 (0.63 to 1.19) 1.05 (0.76 to 1.45)
21 to 30 years 258 49 0.93 (0.69 to 1.24) 0.92 (0.68 to 1.24) 1.06 (0.78 to 1.44)
>30 years 340 61 1.11 (0.85 to 1.45) 1.30 (1.00 to 1.70) 1.56 (1.19 to 2.05)
P-value, test for trende 0.67 0.07 0.004
aHRs adjusted for age at diagnosis (≤39, 40 to 49, 50 to 59, 60 to 69, ≥70 years). bHRs adjusted for age at diagnosis (≤39, 40 to 49, 50 to 59, 60 to 69, ≥70 years),
year of diagnosis (≤1994, 1995 to 1999, 2000 to 2004, ≥2005), age at menarche (≤11, 12, 13, ≥14 years), parity (0, 1, 2, ≥3), menopausal status (premenopausal,
postmenopausal), current hormone replacement therapy use (yes, no), first degree family history of breast cancer (yes, no), estrogen and progesterone receptors
positivity (positive, negative, not investigated), histological grade (well, moderately, poorly differentiated), size of the tumor (≤10, 11 to 20, 21 to 30, 31 to 40, >40
mm, no pathological investigation), regional or distant involvement (node-negative, 1 to 3 positive nodes, ≥4 positive nodes, unknown nodal involvement, distant
metastases), locoregional treatment (mastectomy, breast-conserving surgery, no surgery), neoadjuvant therapy (yes, no), adjuvant endocrine therapy (yes, no),
adjuvant chemotherapy (yes, no). cReference category. dAmong the 1,079 current smokers, number of pack years of smoking, number of cigarettes smoked
and duration of smoking were unknown for 296, 60 and 290 women, respectively. eP for trend in hazard ratios comparing current smokers further categorized
based on number of pack years of smoking, number of cigarettes smoked daily or duration of smoking, to never smokers. HR, hazard ratio; CI, confidence interval.
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smokers. Among current smokers at diagnosis, breast
cancer-specific mortality was 52% higher (HR = 1.52, 95%
CI: 1.15 to 2.00) for women with more than 30 pack years
of smoking, 32% higher (HR = 1.32, 95% CI: 1.02 to 1.70)
among those smoking more than 20 cigarettes per day
and 56% higher (HR = 1.56, 95% CI: 1.19 to 2.05) among
those smoking for more than 30 years, compared to never
smokers. An increase in the breast cancer-specific mortal-
ity rate of 52% among women with more than 30 pack
years of smoking as compared with never smokers would
be associated with an absolute reduction of 9.1% in the
ten-year breast cancer survival in this group.
With respect to our sensitivity analyses, results based
on complete case analysis or on the analysis using miss-
ing indicator variables for confounders were similar or
differed only slightly from those obtained with multiple
imputation. For instance, when compared to never smokers,
the HRs for those who had more than 30 pack years of
smoking were 1.52 (1.15 to 2.00) in the main analysis, 1.45
(1.05 to 2.02) in the complete cases analysis (see Additional
file 1), and 1.52 (1.15 to 2.01) (see Additional file 2) in the
analysis with missing indicator variables. In the main
analysis with multiple imputation, in the subset ofcases (n = 2,315) with complete data including alcohol
use, or in the analysis using indicator variables for
missing data on confounders other than alcohol (n = 3,099),
further adjustment for alcohol use increased rather than
decreased multivariate adjusted HRs relating smoking to
breast cancer-specific mortality by 2% or less. Sensitivity
analyses of confounding effects suggest that body mass
index and diabetes had no confounding effects, while
tumor characteristics had notable confounding effects.
Multivariate adjusted HRs relating smoking at diagnosis to
breast cancer-specific mortality from models that included
characteristics of the tumor (receptor status, grade, size of
tumor and stage) were generally similar or slightly higher
than those that excluded these characteristics individually
from the models. However, when all these characteristics
were excluded from the model, the strength of the associ-
ation was reduced. For instance, exclusion of all such
tumor characteristics from the full model decreased the
HR associated with current smoking from 1.15 to 1.02
(−11.3%).
Interactions of smoking status with age at diagnosis,
menopausal status, body mass index, ER/PR status, regional
or distal involvement and treatments were assessed, and
none of these interaction tests was statistically significant
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cator variables for missing data on confounders.
The associations between smoking exposure variables
and all-cause mortality were stronger than those with
breast cancer-specific mortality and were statistically sig-
nificant (all Passociation ≤0.0001) (Table 3). For instance,
all-cause mortality was 17% and 38% higher in former
and current smokers at diagnosis, respectively, as compared
with never smokers. All-cause mortality also increased with
increasing pack years of smoking (Ptrend <0.0001), increas-
ing intensity (Ptrend = 0.0001) and increasing duration of
smoking (Ptrend <0.0001) among current smokers at diag-
nosis, as compared with never smokers. Compared to the
main analysis, HRs were only slightly lower in the complete
case analysis (see Additional file 3) and were similar in the
analysis with missing indicators (see Additional file 4).
Systematic review and meta-analysis of published
findings
A total of 120 records were identified through PubMed
searching and no duplicate was found (Figure 1). Of the
120 records screened, the two reviewers independently
identified the same nine published relevant studies on
the relation of smoking to breast cancer-specific survivalTable 3 All-cause mortality according to smoking exposure a
breast cancer (1987 to 2008)
Smoking status
Number of Crude HR (95
Women Deaths
Neverc 3,510 859 1.00
Former 1,303 267 0.93 (0.81 to
Currentd 1,079 282 1.00 (0.87 to
≤15 pack years 232 52 0.67 (0.51 to
>15 to ≤30 pack years 278 88 1.13 (0.91 to
>30 pack years 273 93 1.30 (1.05 to
P-value, test for trende 0.0003
≤10 cigarettes/day 287 64 0.89 (0.69 to
>10 to ≤20 cigarettes/day 395 114 1.04 (0.86 to
>20 cigarettes/day 337 97 1.08 (0.87 to
P-value, test for trende 0.30
≤20 years 191 54 0.80 (0.61 to
21 to 30 years 258 66 0.81 (0.63 to
>30 years 340 115 1.45 (1.20 to
P-value, test for trende 0.002
aHRs adjusted for age at diagnosis (≤39, 40 to 49, 50 to 59, 60 to 69, ≥70 years). bH
year of diagnosis (≤1994, 1995 to 1999, 2000 to 2004, ≥2005), age at menarche (≤1
postmenopausal), current hormone replacement therapy use (yes, no), first degree
positivity (positive, negative, not investigated), histological grade (well, moderately,
mm, no pathological investigation), regional or distant involvement (node-negative
metastases), locoregional treatment (mastectomy, breast-conserving surgery, no sur
chemotherapy (yes, no). cReference category. dAmong the 1,079 current smokers, numb
were unknown for 296, 60 and 290 women, respectively. eP for trend in hazard ratios co
smoking, number of cigarettes smoked daily or duration of smoking, to never smokers.[4-6,8,9,11,12,15,16]; these studies are summarized in
Table 4 (which includes the present study). Four [9,11,12,16]
of these studies were reported in the review identified on
smoking and breast cancer prognosis published in 2009 [3];
the study from Japan [15] was not included in the 2009 re-
view, and four studies were published after the publication
of the 2009 review [4-6,8]. A recent systematic review pub-
lished in 2012 [5] included only five of the ten studies in
Table 4. To our knowledge, no meta-analysis of smoking at
diagnosis and post-diagnosis breast cancer specific mortality
has been published yet.
Overall, cases of breast cancer were diagnosed be-
tween 1976 and 2012. All except two studies [15,16]
had at least 15 years of potential follow-up. The
present study is the largest with 5,892 cases; the num-
ber of breast cancer cases ranged from 150 to 5,056 in
the other studies. When reported, mean or median age
of participants at diagnosis ranged between 54 and 67 years
[5,6,8,9,11,12]. Most studies (including the present study)
included invasive breast cancer cases of any stage
[4,6,8,12,15,16] and three studies excluded cases of
advanced disease at diagnosis [5,9,11]; one study also
included cases of in situ breast cancer (representing
12% of all cases) [12].t time of diagnosis among 5,892 women with invasive
All-cause mortality
% CI) Agea-adjusted HR (95% CI) Adjustedb HR (95% CI)
1.00 1.00
1.06) 1.10 (0.95 to 1.26) 1.17 (1.01 to 1.34)
1.14) 1.21 (1.05 to 1.39) 1.38 (1.20 to 1.60)
0.89) 0.77 (0.58 to 1.02) 0.89 (0.67 to 1.19)
1.41) 1.37 (1.09 to 1.71) 1.62 (1.29 to 2.03)
1.61) 1.62 (1.30 to 2.01) 1.83 (1.47 to 2.29)
< 0.0001 < 0.0001
1.15) 1.01 (0.79 to 1.31) 1.23 (0.95 to 1.60)
1.27) 1.24 (1.02 to 1.51) 1.36 (1.11 to 1.67)
1.33) 1.41 (1.14 to 1.75) 1.56 (1.26 to 1.94)
0.001 0.0001
1.06) 0.88 (0.66 to 1.17) 1.00 (0.75 to 1.34)
1.04) 1.06 (0.82 to 1.38) 1.24 (0.95 to 1.61)
1.77) 1.65 (1.36 to 2.01) 1.95 (1.59 to 2.38)
< 0.0001 < 0.0001
Rs adjusted for age at diagnosis (≤39, 40 to 49, 50 to 59, 60 to 69, ≥70 years),
1, 12, 13, ≥14 years), parity (0, 1, 2, ≥3), menopausal status (premenopausal,
family history of breast cancer (yes, no), estrogen and progesterone receptors
poorly differentiated), size of the tumor (≤10, 11 to 20, 21 to 30, 31 to 40, >40
, 1 to 3 positive nodes, ≥4 positive nodes, unknown nodal involvement, distant
gery), neoadjuvant therapy (yes, no), adjuvant endocrine therapy (yes, no), adjuvant
er of pack years of smoking, number of cigarettes smoked and duration of smoking
mparing current smokers further categorized based on number of pack years of
HR, hazard ratio; CI, confidence interval.
120 records identified through PubMed
106 Records excluded with minimal uncertainty based on title or abstract:
53 studies on breast cancer risk factors
9 studies on all-cause or breast cancer mortality in women
6 studies on risk for cancer or CVD after breast cancer
23 studies on progression of breast cancer (not on smoking)
15 unrelated studies
14 full-text articles retrieved for consultation
(1 additional paper identified in a reference list)
6 Full-text articles excluded:
3 studies on overall survival after breast cancer
3 studies on progression of breast cancer (without reference to smoking)
9 studies included in qualitative synthesis and meta-analysis
Figure 1 Search strategy and study selection process used in the meta-analysis of the association between smoking status and breast
cancer-specific mortality.
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http://breast-cancer-research.com/content/16/2/R42The assessment of smoking was based on information re-
ported by patients at the time of or shortly after diagnosis
of breast cancer (as in the present study) [4,11,12,15,16], in
the year following diagnosis [8], in the two years preceding
the diagnosis (Nurses’ Health Study, NHS) [9], several years
before diagnosis (mean 6.7 years before diagnosis) [6]
or in the three years following diagnosis [5]. The pro-
portion of current smokers ranged between 8% and
27% ([4,5,8,9,11,12,15,16] and the present study) but
reached 50% in one study [6]. All studies measured






Tominaga et al. [15] Japan 1986 to 1995 I to IV
Manjer et al. [12] Sweden 1977 to 1996 0 to IV
Fentiman et al. [11] UK 1984 to 2004 I to II
Sagiv et al. [16] USA 1996 to 2002 Invasive
Holmes et al. [9] USA 1978 to 2002 I to III
Dal Maso et al. [8] Italy 1991 to 2006 I to IV
Hellmann et al. [6] Denmark 1976 to 2007 Loc/reg/m
Braithwaite et al. [5] USA 1997 to 2012 I to III
Warren et al. [4] USA 1982 to 2010 Loc/reg/m
Bérubé et al. Canada 1987 to 2008 Loc/reg/m
Loc/reg/met, Local, regional and metastatic disease.of smoking cessation or variation in smoking habit
over time after breast cancer diagnosis.
Deaths were identified through linkage to national
registries, and cause of death from death certificates (as
in the present study) [4,5,12,16] supplemented as needed
by reviewing medical records [8], or from medical re-
cords only [11,15]. In the NHS (2007) [9], deaths were
usually reported by families or postal authorities and
supplemented with a search in the National Death Index,
and cause of death was based on death certificates. The
percentage of deaths attributable to breast cancer was 42%on between smoking status and breast cancer‐specific
No. participants Breast cancer deaths
Current Never Current Never
smokers smokers smokers smokers
68 325 - -
216 491 48 81
40 67 - -
252 568 28 52
1,018 2,112 216 357
290 934 80 248
et 212 120 96 48
173 1194 25 111
et 143 480 - -
et 1,079 3,510 185 583
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http://breast-cancer-research.com/content/16/2/R42[12], 50% [5], 59% [16], 65% [9], 68% (the present study),
79% [8] and 100% [15].
All HRs are minimally adjusted for age at diagnosis
and stage (except in [16]). The HRs in [6,9] and in the
present study are also adjusted for body mass index
(BMI). The HRs in [8,9] and in the present study are
also adjusted for year of diagnosis; women were re-
cruited in only one calendar year in [16]. All HRs except
one [12] are additionally adjusted for potential con-
founders other than age, stage, BMI or year of diagnosis.
Results from available studies on smoking at diagno-
sis and breast cancer-specific mortality after diagnosis
[4-6,8,9,11,12,15,16] are presented in Table 4 and Figure 2.
The summary breast cancer-specific HR for current
smokers as compared with never smokers is 1.33 (95% CI:
1.12 to 1.58); test for overall effect, random-effects
model; P = 0.001). Based on the Q statistic (P = 0.0005)
and the I2 index (70%), there was rather high [35] heterogen-
eity between studies (Figure 2 and Figure 3). After the
exclusion of the three studies most likely responsible
for heterogeneity [4,5,12], there was no more heterogen-
eity between studies (Q statistic: P = 0.45; I2 index = 0%),
and the summary HR for current smokers at diagnosis as
compared to never smokers is 1.10 (95% CI: 1.01 to 1.20).
The test for overall effect was identical whether based on
fixed-effects or random-effects models (P = 0.03). These
three papers [4,5,12] are in our view of good quality.
Discussion
In this large cohort of breast cancer patients, breast
cancer-specific mortality increased with total, intensity
or duration of smoking at diagnosis. Moreover, the
meta-analysis of all studies identified in this systematic
review shows a statistically significant increased breast
cancer-specific mortality among current smokers comparedFigure 2 Forest plot with study specific and random effects for assoc
cancer specific-mortality. In two studies, the authors present multivariate
1.41 and 1.08 in Table 2 in Fentiman [11] and HRs of 2.14 and 1.95 in Table
was adjusted for the most complete set of prognostic factors including ag
for cases currently smoking <15 cigarettes/day (HR: 1.39) and those smokin
corresponding HRs among current smokers were weighted in proportion t
combined. The summary HR and 95% CI are from random-effects models.to non-smokers at diagnosis. Thus, current evidence indi-
cates that smoking at diagnosis is associated with a reduced
survival from breast cancer itself. Moreover, among avail-
able studies on smoking at diagnosis and overall survival
[4-14,16,36-38], most [4-14,16] - including our own - show
that current smokers have lower overall survival compared
to never smokers.
Smoking status at time of diagnosis is a strong indica-
tor of continued smoking after diagnosis since, among
smoking women with breast cancer, only 4% are re-
ported to have stopped smoking post-diagnosis [39]. To
our knowledge, no study has compared breast cancer
specific survival of smokers at diagnosis who continue
smoking to that of smokers at diagnosis who stop smok-
ing. Moreover, if smoking cessation has an effect on
post-diagnosis breast cancer specific mortality, the time
required for this effect of smoking cessation to be seen
needs to be examined.
Smoking is suspected to play a role in the initiation
and growth of many cancers, including breast cancer.
Experimental evidence is accumulating on the contribu-
tion of nicotine to tumor growth and metastasis [40].
The effects of nicotine might be mediated through the
nicotinic acetylcholine receptors, which are expressed in
human breast cancer cells and regulate diverse signaling
pathways involved in cell proliferation, angiogenesis,
apoptosis and also in metastatic dissemination of the
primary tumor. Such findings suggest that smoking can
affect the incidence as well as the course of cancer. Epi-
demiological findings suggest that smoking is associated
with increased breast cancer incidence [41].
Many women diagnosed with breast cancer are smokers –
18% of women in this Canadian population and 15% to 20%
of US cancer survivors [1,42]. Among such a large popula-
tion of smokers, actions aimed at smoking cessation can beiation between smoking status (current versus never) and breast
adjusted HRs for current smokers from two distinct models (HRs of
1 in Manjer [12]); the present meta-analysis is based on the HR that
e. In the study by Dal Maso et al. [8] results were published separately
g ≥15 cigarettes/day (HR: 1.23), as compared with never smokers; the
o the numbers in each subgroup (182 and 108, respectively) and then
CI, confidence interval; HR, hazard ratio.
Figure 3 Funnel plot with a triangular 95% confidence region.
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http://breast-cancer-research.com/content/16/2/R42justified by the strong and widely accepted association of
smoking with overall survival [43]. The present study sup-
ports the idea that smoking could also be detrimental in
terms of survival from the disease itself – information which
could represent an important additional incentive for smok-
ing cessation among smoking women with breast cancer.
We previously reported that some women with early breast
cancer undertake healthful behavior changes on their own
and that these changes are generally coherent with current
guidelines for things such as diet and physical activity [44].
However, as mentioned above, only 4% of smoking women
with breast cancer are reported to have stopped smoking
post-diagnosis [39].
This study has strengths and weaknesses. First, in this,
as in most previous studies on the subject, smoking ex-
posure was self-reported at time of breast cancer diag-
nosis. Moreover, we have no information on passive
smoking. Second, cause of death was based on death
certificates. As a result, the accuracy of causes of death
may be imperfect [45], but this is unlikely related to
smoking status. Third, multivariate adjusted models took
into account a large set of potential confounders, includ-
ing the main breast cancer prognostic factors. Neverthe-
less, residual confounding is possible and may be due,
for instance, to unmeasured factors, such as mode of de-
tection [46], delay in treatment [47], other lifestyle fac-
tors at the time of diagnosis (for example, physical
activity [2,23]) or after diagnosis (for example, physical
activity or weight control [2,3,23]). Finally, the present
study is based on the experience of only one breast cen-
ter. However, during the years 2002 to 2006, patients
treated in this center represented 78% of all newly diag-
nosed invasive breast cancer cases among women living
in this area. The study population is similar to Canadian
women both with regard to smoking behavior at the
time of diagnosis and to breast cancer survival. For in-
stance, between 23% (1999) and 16% (2008) of Canadian
women [48] and 18% (1987 to 2008) of the study popu-
lation were current smokers. The five-year (87%) andten-year (79%) breast cancer-specific survival estimates
in the present study were similar to five-year (86% to
88% [49-51]) and ten-year (80% to 82% [49,50]) relative
survival rate estimates available from Canadian national
statistics.
Between-study heterogeneity that was apparent in the
meta-analysis needs to be clarified. In our view, this het-
erogeneity is not explained by the quality of studies; al-
most all available studies were of good quality. However,
the list of confounders taken into account in the analysis
varies substantially from one study to the other. We can-
not exclude the possibility of a publication bias.
Conclusions
In summary, our new findings combined with those of
previous studies indicate that smoking at diagnosis is as-
sociated with a reduction of breast cancer-specific sur-
vival as well as overall survival. The possibility that
smoking cessation could improve survival from breast
cancer itself needs to be assessed. If smoking after diag-
nosis was shown to be detrimental in terms of survival
from the disease itself, this would represent an import-
ant additional incentive for smoking cessation efforts
among smoking women with breast cancer and among
physicians who care for them.
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